The partnership involves the use of Actinium’s Antibody Warhead Enabling tech for conjugation and labeling of targeting agents from Astellas.

 A research collaboration established in early 2018 between Actinium Pharmaceuticals and Astellas Pharma continues to progress. As part of the deal, Actinium is responsible for developing Actinium-225 Radio-Conjugates (ARCs) of selected Astellas targeting agents using its Actinium Warhead Enabling (AWE) platform technology and conducting preclinical studies of the generated ARCs. In return, Actinium has received up-front payment and research funding from Astellas.

Recently, the two companies announced that Actinium successfully completed the second module of the research and option agreement with Astellas and initiated the third and final module.